Sarepta price target raised to $93 from $82 at Needham

Needham raised the firm’s price target on Sarepta to $93 from $82 and keeps a Buy rating on the shares after its Q3 results. The company’s “strong” first quarter for Elevidys sales is indicative of pent-up demand for a novel DMD therapeutic and helped Sarepta achieve non-GAAP profitability for the first time, the analyst tells investors in a research note.